Přihlásit pro zobrazení organizačních a smluvních cen.
Vybrat velikost
Změnit zobrazení
| Vám/SKU | Dostupnost | Cena |
|---|---|---|
1 kit | Obraťte se na zákaznický servis a vyžádejte si informaci o dostupnosti. | 19 600,00 Kč |
O této položce
NACRES:
NA.23
UNSPSC Code:
12161503
Storage temp.:
2-8°C
19 600,00 Kč
Obraťte se na zákaznický servis a vyžádejte si informaci o dostupnosti.
Technický servis
Potřebujete pomoc? Náš tým zkušených odborníků je vám k dispozici.
Dovolte nám, abychom vám pomohliQuality Segment
description
Kit components :
PEGPLA-L-M (919942-500mg)
PEGPLA-H-M (919934-500mg)
Stabilizer-Nano (907766-5g), PEG-PLA drug formulation screening kit, for synthesis of PEGylated PLA nanoparticles
application(s)
advanced drug delivery
storage temp.
2-8°C
General description
NanoFabTx™ PEG-PLA drug formulation screening kit is a nanoformulation kit containing rationally selected PEGylated PLA polymers that have been used widely for controlled drug release of many different types of therapeutic molecules. The kit contains protocols for two different particle synthesis methods:
- A Nanoprecipitation protocol to prepare drug-encapsulated nanoparticles in standard laboratory glassware.
- A Microfluidics protocol using commercial platforms or syringe pumps.
Application
NanoFabTx™ PEG-PLA drug formulation screening kit enables users to encapsulate a wide variety of therapeutic drug molecules in specifically sized, biodegradable, PEGylated PLA nanoparticles. By simplifying the chemistry and providing an easy-to-use toolkit with step-by-step instructions, our NanoFabTx™ nanoformulation screening kit helps researchers achieve reproducible synthesis of drug encapsulating nanoparticles with narrow size dispersity, eliminating the need for lengthy trial-and-error optimization. Suitable for biomedical research applications such as oncology, immuno-oncology, gene delivery, and vaccine delivery, PEG-PLA nanoparticles, made using the NanoFabTx™ PEG-PLA drug formulation screening kit, are designed for maximizing the encapsulation of hydrophobic drugs to minimize the time and expensive wasted reagents of synthetic optimization.
Features and Benefits
- Includes tested protocols with step-by-step instructions for nanoprecipitation or microfluidics-based syntheses
- Requires minimal laboratory setup
- Optimized to achieve monodisperse, homogenously shaped, biodegradable, PEGylated PLA nanoparticles in any size between 60 and 100 nm
- Formulated to maximize the encapsulation of hydrophobic drugs
- Includes two different PEGylated PLAs
Legal Information
NANOFABTX is a trademark of Sigma-Aldrich Co. LLC
1 of 1
Tato položka | |||
|---|---|---|---|
| description for synthesis of PEGylated nanoparticles | description PEGPLGA-50H | description for synthesis of cationic (DOTAP) liposomes | description for synthesis of 100 and 200 nm particles |
| Quality Level 100 | Quality Level 100 | Quality Level 100 | Quality Level 100 |
| storage temp. 2-8°C | storage temp. 2-8°C | storage temp. −20°C | storage temp. 2-8°C |
| description PEG-PLA drug formulation screening kit, for synthesis of PEGylated PLA nanoparticles | description - | description - | description - |
| application(s) advanced drug delivery | application(s) advanced drug delivery | application(s) - | application(s) advanced drug delivery |
Skladovací třída
10 - Combustible liquids
Vyberte jednu z posledních verzí:
Již tento produkt vlastníte?
Dokumenty související s produkty, které jste v minulosti zakoupili, byly za účelem usnadnění shromážděny ve vaší Knihovně dokumentů.


